Showing 1931-1940 of 5771 results for "".
- ASCRS Introduces Richard L. Lindstrom Lecture for 2021 Annual Meetinghttps://modernod.com/news/ascrs-introduces-richard-l-lindstrom-lecture-for-2021-annual-meeting/2478960/The American Society of Cataract and Refractive Surgery (ASCRS) has announced the inaugural Richard L. Lindstrom Lecture and Medal, which will be delivered along with other distinguished lectures at the 2021 ASCRS Annual Meeting in Las Vegas, Nevada. The Richard L. Lindstrom Lecture and Me
- Samsara Vision and Medevise Consulting Announce European Partnershiphttps://modernod.com/news/samsara-vision-and-medevise-consulting-announce-european-partnership/2478956/Samsara Vision announced it will partner with Medevise Consulting to build a dedicated commercial organization to support Samsara Vision’s Tsert SI Implantable Miniature Telescope (IMT) (by Isaac Lipshitz). The two companies will collaborate to advance clinical research, coordinate reimbursement,
- Adverum Announces Shortened Timelines and Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMDhttps://modernod.com/news/adverum-announces-shortened-timelines-and-clear-development-path-for-advm-022-intravitreal-gene-therapy-in-wet-amd/2478955/Adverum Biotechnologies announced that it has gained alignment with the FDA on the clinical development path for ADVM-022, an investigational single, in-office intravitreal (IVT) injection gene therapy for the treatment of wet age-related macular degeneration (AMD
- Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-36-million-series-a-financing-to-advance-development-of-novel-presbyopia-correcting-eye-drop/2478952/Visus Therapeutics announced the close of a $36 million Series A Preferred Stock financing to advance the clinical development program for the company’s lead asset, Brimochol, an investigational drug designed to be a
- Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patientshttps://modernod.com/news/alteogen-announces-completion-of-phase-1-clinical-trial-of-aflibercept-biosimilar-in-wet-amd-patients/2478948/Alteogen announced that it has completed phase 1 clinical trial of Eylea Biosimilar (ALT-L9). The clinical trial was conducted at 4 major hospitals in Korea: Asan Hospital, Seoul National University Bundang Hospital, Samsung Seoul Hospital, and Severance Hospital. Alteogen has strengthened compet
- Ocuphire Announces Publication of MIRA-1 Phase 2b Results Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxolhttps://modernod.com/news/ocuphire-announces-publication-of-mira-1-phase-2b-results-demonstrating-reduction-of-pharmacologically-induced-mydriasis-by-nyxol/2478940/Ocuphire Pharma announced that the results from the MIRA-1 (NCT04024891) phase 2b clinical trial evaluating the safety and efficacy of Nyxol in the reversal of mydriasis have been published in Optometry and Visual Science. The article will appear in the print edition and is available on-
- Azura Ophthalmics Announces Positive Topline Results From Phase 2 Program of Investigational Treatment for MGDhttps://modernod.com/news/azura-ophthalmics-announces-positive-topline-results-from-phase-2-program-of-the-companys-investigational-treatment-for-mgd/2478934/Azura Ophthalmics announced topline results from a phase 2 program evaluating the company’s investigational therapy for the treatment of Meibomian gland dysfunction (MGD). AZR-MD-001 met its primary endpoints showing improvements in signs and symptoms of MGD, reaching statistical significance com
- Iridex Announces Strategic Collaboration With Topconhttps://modernod.com/news/iridex-announces-strategic-collaboration-with-topcon-corporation/2478933/Iridex announced that it has entered into a strategic collaboration with Topcon. The collaboration between Iridex and Topcon includes three main agreements: an Exclusive Distribution Agreement, an Asset Purchas
- Eyenovia Announces FDA Acceptance of Filing of NDA for MydCombihttps://modernod.com/news/eyenovia-announces-fda-acceptance-of-the-mydcombi-nda/2478929/Eyenovia announced that the FDA has accepted the company’s new drug application (NDA) for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent. If approved, MydCombi would be the first microdosed ocular therapeutic applied with a high precision smart delivery system, the Optejet.
- SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Advance Gene Therapieshttps://modernod.com/news/saliogen-therapeutics-announces-closing-of-20-million-series-a-financing-to-advance-gene-therapies/2478925/SalioGen Therapeutics announced that it has closed a $20 million Series A financing to support the preclinical validation of the company’s proprietary Exact DNA Integration Technology (EDIT) platform for the development of durable, safe and affordable in vivo gene the